SCHEMBL4568196

SCHEMBL4568196

CCOC(=O)c1cccc(Cc2c(-c3ccccc3)[nH]c3cc(C(F)(F)F)ccc23)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
MAPK10 P53779 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX5 P09917 1/20 0.41
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
DHODH Q02127 1/20 0.41
HTT P42858 1/20 0.41
CYP1A2 P05177 1/20 0.40
GABRP O00591 2/20 0.40
GABRD O14764 2/20 0.40
GABRA1 P14867 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568198 0.89 MAPT (0.41) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4568207 0.88 MRGPRX4 (0.46) CYP1A2MCL1
SCHEMBL4568517 0.85 KDM4E (0.46) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4568197 0.84 KDM4E (0.42) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL11979687 0.83 MCL1 (0.44) MCL1DRD2HTR2AHTR2C
SCHEMBL3702863 0.83 MAPT (0.43) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL15975189 0.82 MCL1 (0.52) MCL1
SCHEMBL10314423 0.82 PDE3B (0.42) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4568493 0.82 MTNR1A (0.41) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL4568504 0.81 MAPT (0.41) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPT 3199/4885KDM4E 3521/4885ALDH1A1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.